Aliases & Classifications for Thrombocytosis

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 72 28 51 41 14 69
Thrombocythaemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2228
MeSH 41 D013922
NCIt 46 C35530
UMLS 69 C0836924

Summaries for Thrombocytosis

Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to thrombocythemia 1 and polycythemia vera. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Anagrelide and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 72 Thrombocytosis (or thrombocythemia) is the presence of high platelet counts in the blood, and can be... more...

Related Diseases for Thrombocytosis

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 357)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 33.1 MPL THPO
2 polycythemia vera 30.8 EPO IL3 JAK2 MPL SELP TET2
3 myeloproliferative neoplasm 30.4 JAK2 MPL TET2
4 neutrophilia, hereditary 30.3 CRP CSF2 IL6
5 splenomegaly 30.3 EPO JAK2 MPL
6 refractory anemia 30.3 EPO IL3 JAK2 MPL TET2
7 iron deficiency anemia 30.1 CRP EPO IL6 THPO
8 essential thrombocythemia 30.1 EPO F2 F3 IL11 IL3 JAK2
9 thrombocytopenia 30.0 F3 IL11 MPL THPO
10 poems syndrome 29.7 EPO IL6
11 polycythemia 29.7 EPO IL3 JAK2 MPL TET2 THPO
12 myelofibrosis 29.6 EPO IL3 JAK2 MPL TET2 THPO
13 myelodysplastic myeloproliferative cancer 29.5 CSF2 JAK2 TET2
14 peritonitis 29.5 CRP F2 IL6
15 central retinal vein occlusion 29.4 F2 IL6 SERPINC1
16 deficiency anemia 29.3 CRP EPO IL11 IL3 IL6 THPO
17 retinal vein occlusion 29.3 F2 IL6 SERPINC1
18 burns 29.2 CSF2 SERPINC1
19 leukemia, chronic myeloid 29.2 CSF2 EPO IL3 JAK2 MPL THPO
20 pancytopenia 29.2 CSF2 EPO MPL THPO
21 monocytic leukemia 29.1 CSF2 F3 IL6
22 eosinophilic gastroenteritis 29.1 CSF2 IL3
23 pulmonary embolism 28.9 CRP F2 F3 SERPINC1
24 von willebrand's disease 28.9 F2 F3 SELP
25 thrombophilia due to thrombin defect 28.9 F2 F3 SERPINC1
26 thrombosis 28.8 F2 F3 JAK2 SELP SERPINC1
27 coronary artery anomaly 28.7 CRP IL6 SELP
28 budd-chiari syndrome 28.7 F2 F3 JAK2 MPL SERPINC1
29 portal vein thrombosis 28.7 F2 JAK2 SELP SERPINC1
30 inflammatory bowel disease 28.7 CRP IL11 IL6 JAK2 SELP
31 acute myocardial infarction 28.6 CRP F3 SELP SERPINC1
32 thrombophilia 28.6 F2 F3 JAK2 SERPINC1
33 leukemia, acute myeloid 28.6 CSF2 F3 IL3 JAK2 MPL TET2
34 heparin-induced thrombocytopenia 28.5 F3 SELP SERPINC1
35 myelodysplastic syndrome 28.4 CSF2 EPO IL11 IL3 JAK2 MPL
36 purpura 28.4 CRP F2 F3 MPL SERPINC1 THPO
37 myocardial infarction 28.1 CRP F2 F3 IL6 SELP SERPINC1
38 heart disease 28.0 CRP F2 F3 IL6 SERPINC1
39 vascular disease 28.0 CRP F3 SELP SERPINC1
40 arteries, anomalies of 27.2 CRP F2 F3 IL6 SELP SERPINC1
41 erythromelalgia 11.2
42 thrombocythemia 3 11.0
43 thrombocythemia with distal limb defects 11.0
44 thrombocythemia, x-linked 10.9
45 thrombocythemia 2 10.9
46 thrombocytopenia 3 10.5 MPL THPO
47 dyskeratosis congenita, autosomal dominant 6 10.5 MPL THPO
48 vibrio vulnificus infection 10.5 EPO IL6
49 acquired thrombocytopenia 10.5 IL11 THPO
50 acquired polycythemia 10.5 EPO JAK2

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis

Symptoms & Phenotypes for Thrombocytosis

MGI Mouse Phenotypes related to Thrombocytosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 CSF2 IL6 EPO JAK2 F2 MPL
2 cardiovascular system MP:0005385 10.11 CRP F3 CSF2 IL6 EPO F2
3 homeostasis/metabolism MP:0005376 10.11 CSF2 IL6 EPO JAK2 F2 MPL
4 immune system MP:0005387 10.1 CSF2 IL6 EPO JAK2 F2 MPL
5 embryo MP:0005380 9.98 F3 CSF2 EPO JAK2 F2 MPL
6 integument MP:0010771 9.8 F3 CSF2 IL6 EPO JAK2 F2
7 mortality/aging MP:0010768 9.65 F3 CSF2 IL6 EPO JAK2 F2
8 liver/biliary system MP:0005370 9.63 IL6 EPO JAK2 SELP SERPINC1 TET2
9 respiratory system MP:0005388 9.1 F3 CSF2 IL6 EPO F2 SELP

Drugs & Therapeutics for Thrombocytosis

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2 127-07-1 3657
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
5 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
6
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-86-4 3871
7 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
9 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
12
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
14
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
15
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
16
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
20
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
24
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
25
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
26
Morphine Approved, Investigational Phase 3 57-27-2 5288826
27
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
28
Ribavirin Approved Phase 3 36791-04-5 37542
29 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
30
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
31
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 460612 4053
32 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
33
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
34
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
37 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
38 Analgesics Phase 3,Phase 2,Phase 1
39 Anesthetics Phase 3
40 Anesthetics, Dissociative Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
44 Excitatory Amino Acid Antagonists Phase 3
45 Excitatory Amino Acids Phase 3
46 Neurotransmitter Agents Phase 3,Phase 2
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 2,Phase 1
50 Dermatologic Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 257)

# Name Status NCT ID Phase Drugs
1 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
7 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
8 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
9 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
11 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
12 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
13 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
14 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
15 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
16 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
19 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
27 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
28 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
29 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
30 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
31 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
32 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
33 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
34 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
35 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
36 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
37 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
38 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
39 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
40 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
41 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
42 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
43 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
44 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Completed NCT00413634 Phase 2 anagrelide hydrochloride
45 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
46 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib
47 A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Completed NCT02125318 Phase 2 Anagrelide CR
48 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT01236638 Phase 2 Momelotinib
49 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT00935987 Phase 1, Phase 2 CYT387
50 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: thrombocytosis

Genetic Tests for Thrombocytosis

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 28

Anatomical Context for Thrombocytosis

MalaCards organs/tissues related to Thrombocytosis:

38
Myeloid, Bone, Bone Marrow, Liver, Lung, Testes, T Cells

Publications for Thrombocytosis

Articles related to Thrombocytosis:

(show top 50) (show all 739)
# Title Authors Year
1
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
2
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 29404744 )
2018
3
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. ( 29282219 )
2018
4
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. ( 29442537 )
2018
5
Integrated micro/messenger RNA regulatory networks in essential thrombocytosis. ( 29420626 )
2018
6
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy. ( 28984013 )
2018
7
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
8
Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. ( 29368262 )
2018
9
Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. ( 29373977 )
2018
10
Therapeutic Thrombocytapheresis for Symptomatic Thrombocytosis in Hemato-Oncology Patients. ( 29205870 )
2018
11
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. ( 29240268 )
2018
12
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
13
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
14
Thrombocytosis in children: Clinico-hematological profile from a single centre in Eastern India. ( 29403202 )
2018
15
Sickle cell trait with I^-thalassemia, elliptocytosis, and thrombocytosis. ( 28882837 )
2017
16
Refractory anemia with ring sideroblasts and thrombocytosis. ( 28401094 )
2017
17
Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma. ( 28988254 )
2017
18
Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors. ( 28761360 )
2017
19
Thrombocytosis as a prognostic factor in inflammatory breast cancer. ( 28831670 )
2017
20
Isolated thrombocytosis in chronic myeloid leukemia without significant leukocytosis. ( 28781272 )
2017
21
Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease. ( 28740456 )
2017
22
A Violaceous, Photodistributed Cutaneous Eruption and Leg Ulcer in a Woman With Essential Thrombocytosis. ( 28877306 )
2017
23
Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma. ( 28668174 )
2017
24
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
25
Acute renal infarction: a presentation of essential thrombocytosis. ( 29055434 )
2017
26
Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis. ( 28677819 )
2017
27
Ertapenem-Induced Thrombocytosis. ( 28652947 )
2017
28
Clinical relevance of thrombocytosis in primary care. ( 28860284 )
2017
29
Clinical and laboratory assessment of a patient with thrombocytosis. ( 29019736 )
2017
30
The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis. ( 28588739 )
2017
31
Thrombocytosis in gynecological cancers. ( 28643732 )
2017
32
The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ( 29068570 )
2017
33
Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. ( 28694147 )
2017
34
Thrombocytosis in 715 Dogs (2011-2015). ( 28895208 )
2017
35
The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy. ( 28895417 )
2017
36
Extending Carotid Artery Thrombus Associated with Thrombocytosis. ( 29279468 )
2017
37
Thrombocytosis-related glomerulopathy in a patient with hyposplenia. ( 28653342 )
2017
38
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 27714462 )
2017
39
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. ( 27734130 )
2017
40
Identification of<i>MPL</i>R102P Mutation in Hereditary Thrombocytosis. ( 28979237 )
2017
41
Magnitude of reactive thrombocytosis and associated clinical conditions in dogs. ( 28780529 )
2017
42
Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies. ( 28870890 )
2017
43
The Significance of Pretreatment Thrombocytosis and Its Association With Neutrophilia in Patients With Surgically Treated Endometrial Cancer. ( 28604454 )
2017
44
Cyclic thrombocytopenia synchronizing with the menstrual cycle showing periodic phases of thrombocytopenia and rebound thrombocytosis. ( 28413179 )
2017
45
Iron deficiency and thrombocytosis. ( 27870058 )
2017
46
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. ( 28188970 )
2017
47
Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma. ( 27532673 )
2016
48
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. ( 27301073 )
2016
49
Jack 2 negative essential thrombocytosis with portal vein thrombosis and portal cavernoma formation - A case report. ( 27728317 )
2016
50
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. ( 26608331 )
2016

Variations for Thrombocytosis

Expression for Thrombocytosis

Search GEO for disease gene expression data for Thrombocytosis.

Pathways for Thrombocytosis

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 CSF2 EPO F2 IL11 IL3 IL6
2
Show member pathways
13.35 EPO F2 IL11 IL3 IL6 JAK2
3
Show member pathways
13.25 CSF2 IL11 IL3 IL6 JAK2 THPO
4
Show member pathways
13.14 CSF2 IL11 IL3 IL6 JAK2 THPO
5
Show member pathways
13.05 CSF2 F2 F3 IL3 JAK2 MPL
6
Show member pathways
12.88 F2 IL3 IL6 JAK2 THPO
7 11.94 F2 F3 SERPINC1
8 11.9 IL11 IL3 IL6 THPO
9 11.76 F3 IL6 JAK2
10
Show member pathways
11.75 F2 MPL THPO
11
Show member pathways
11.72 CSF2 IL6 JAK2
12 11.7 CSF2 IL11 IL6
13 11.7 EPO IL3 IL6 JAK2
14
Show member pathways
11.67 CRP IL6 JAK2
15 11.62 CSF2 EPO IL11 IL3 IL6 THPO
16
Show member pathways
11.61 CSF2 EPO IL11 IL3 IL6 JAK2
17 11.56 CSF2 EPO IL11 IL3 IL6 MPL
18
Show member pathways
11.48 IL11 IL6 JAK2
19 11.39 EPO IL11 IL3 IL6
20 11.35 CSF2 EPO IL3 IL6
21 11.12 CRP JAK2 MPL THPO
22 11.06 CSF2 IL11 IL3 IL6
23 11.03 CSF2 IL11 IL3 IL6
24 10.89 CRP IL6
25 10.85 CSF2 IL11 IL3 IL6 THPO

GO Terms for Thrombocytosis

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRP CSF2 EPO F2 F3 IL11
2 extracellular space GO:0005615 9.36 CRP CSF2 EPO F2 F3 IL11

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 CSF2 EPO F2 IL11 IL3 IL6
2 blood coagulation GO:0007596 9.78 F2 F3 JAK2 SERPINC1
3 cytokine-mediated signaling pathway GO:0019221 9.72 F3 IL3 IL6 JAK2 MPL
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 F2 JAK2 SELP
5 hemostasis GO:0007599 9.67 F2 F3 SERPINC1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL11 IL3 IL6 JAK2
7 positive regulation of DNA replication GO:0045740 9.61 CSF2 EPO IL3
8 regulation of blood coagulation GO:0030193 9.55 F2 SERPINC1
9 myeloid cell differentiation GO:0030099 9.54 TET2 THPO
10 negative regulation of lipid storage GO:0010888 9.52 CRP IL6
11 regulation of receptor activity GO:0010469 9.5 CSF2 EPO F2 IL11 IL3 IL6
12 positive regulation of STAT protein import into nucleus GO:2000366 9.46 F2 IL6
13 acute-phase response GO:0006953 9.46 CRP EPO F2 IL6
14 thrombopoietin-mediated signaling pathway GO:0038163 9.4 MPL THPO
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.02 CSF2 EPO IL3 IL6 JAK2

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 EPO IL11 IL3 IL6 THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 JAK2
3 growth factor activity GO:0008083 9.1 CSF2 F2 IL11 IL3 IL6 THPO

Sources for Thrombocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....